Skip to main content

Table 1 Patient characteristics, admission characteristics and clinical outcomes in the SARS-CoV-2, influenza and RSV cohorts

From: Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus

 

SARS-CoV-2 (n = 1243)

Influenza (n = 775)

RSV (n = 242)

Patient characteristics

 Male sex, n (%)

805 (65)

403 (52)

113 (47)

 Age, median (IQR), years

62 (52–73)

69 (54–79)

71 (61–81)

 ≥ 65, n (%)

520 (42)

442 (57)

170 (70)

 CCI, median (IQR), points

1 (0–2)

1 (0–3)

2 (1–3)

  0–1, n (%)

871 (70)

406 (52)

101 (42)

  2–4, n (%)

291 (23)

279 (36)

103 (43)

 ≥ 5, n (%)

81 (7)

90 (12)

38 (16)

 Specific comorbiditiesa

  Diabetes mellitus, n (%)

338 (27)

139 (18)

47 (19)

  Hypertension, n (%)

565 (45)

265 (34)

95 (39)

  Chronic cardiac disease, n (%)

375 (30)

266 (34)

101 (42)

  Chronic respiratory disease, n (%)

444 (36)

233 (30)

82 (34)

  Chronic kidney disease, n (%)

86 (7)

65 (8)

29 (12)

  Malignancy, n (%)

110 (9)

167 (22)

75 (31)

  Immunosuppression, n (%)

192 (15)

236 (30)

100 (41)

  Any of the comorbidities above, n (%)

911 (73)

560 (72)

198 (82)

Admission characteristics

 Respiratory rate ≥ 30 breaths/min, n (%)

393 (32)

262 (34)

75 (31)

 Systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg, n (%)

340 (28)

346 (45)

99 (42)

 Non-alert, n (%)

117 (10)

55 (9)

15 (8)

 Antibiotic administered at admission (outside the ICU), n (%)

407 (33)

650 (84)

213 (88)

  Third-generation cephalosporins, n (%)

311 (25)

436 (56)

130 (54)

  Penicillins, n (%)

73 (6)

246 (32)

83 (34)

  Fluoroquinolones, n (%)

14 (1)

72 (9)

26 (11)

Clinical outcomes

 LOS, median (days)

8 (5–15)

5 (3–8)

5 (3–9)

 ICU-admission, n (%)

313 (25)

131 (17)

38 (16)

 30-day mortality, n (%)

142 (11)

55 (7)

16 (7)

  1. aSee Additional file 1: Table S1 for included ICD-10 codes per specific comorbidity
  2. CCI, Charlson Comorbidity Index; IQR, Interquartile range; RSV, Respiratory syncytial virus; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2